HomeCompareAVCO vs VYM

AVCO vs VYM: Dividend Comparison 2026

AVCO yields 380.30% · VYM yields 2.37%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AVCO wins by $7922.29M in total portfolio value
10 years
AVCO
AVCO
● Live price
380.30%
Share price
$0.53
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$7922.31M
Annual income
$5,221,452,094.51
Full AVCO calculator →
VYM
Vanguard High Dividend Yield ETF
● Live price
2.37%
Share price
$148.10
Annual div
$3.51
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$27.8K
Annual income
$272.94
Full VYM calculator →

Portfolio growth — AVCO vs VYM

📍 AVCO pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAVCOVYM
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AVCO + VYM cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AVCO pays
VYM pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AVCO
Annual income on $10K today (after 15% tax)
$32,325.54/yr
After 10yr DRIP, annual income (after tax)
$4,438,234,280.33/yr
VYM
Annual income on $10K today (after 15% tax)
$201.60/yr
After 10yr DRIP, annual income (after tax)
$232.00/yr
At 15% tax rate, AVCO beats the other by $4,438,234,048.33/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AVCO + VYM for your $10,000?

AVCO: 50%VYM: 50%
100% VYM50/50100% AVCO
Portfolio after 10yr
$3961.17M
Annual income
$2,610,726,183.73/yr
Blended yield
65.91%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AVCO buys
0
VYM buys
0
No recent congressional trades found for AVCO or VYM in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAVCOVYM
Forward yield380.30%2.37%
Annual dividend / share$2.00$3.51
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$7922.31M$27.8K
Annual income after 10y$5,221,452,094.51$272.94
Total dividends collected$7670.28M$2.6K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: AVCO vs VYM ($10,000, DRIP)

YearAVCO PortfolioAVCO Income/yrVYM PortfolioVYM Income/yrGap
1← crossover$48,730$38,030.04$11,147$237.17+$37.6KAVCO
2$225,338$173,196.79$12,404$242.33+$212.9KAVCO
3$989,615$748,503.08$13,780$247.16+$975.8KAVCO
4$4,131,032$3,072,144.35$15,285$251.67+$4.12MAVCO
5$16,405,542$11,985,337.80$16,932$255.88+$16.39MAVCO
6$62,037,386$44,483,456.11$18,733$259.81+$62.02MAVCO
7$223,589,092$157,209,088.63$20,701$263.46+$223.57MAVCO
8$768,770,844$529,530,516.16$22,852$266.86+$768.75MAVCO
9$2,524,169,252$1,701,584,448.65$25,201$270.01+$2524.14MAVCO
10$7,922,313,194$5,221,452,094.51$27,768$272.94+$7922.29MAVCO

AVCO vs VYM: Complete Analysis 2026

AVCOStock

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People's Republic of China. The company offers medical related consulting services, including research studies, executive education, daily online executive briefings, tailored expert advisory services, and consulting and management services in the areas of immunotherapy and second opinion/referral services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing RNA-based FASH-CARTM cell therapy platform. In addition, the company develops avalon clinical-grade tissue-specific exosome (ACTEX); offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Further, it has strategic partnership with the University of Natural Resources and Life Sciences in Vienna and Austria to develop an S-layer vaccine that could be administered by an intranasal or oral route against SARS-CoV-2 and coronavirus that causes COVID-19 disease; and develops Avalon Cell and Avalon Rehab, as well as promotes standardization related to exosome industry. The company is headquartered in Freehold, New Jersey.

Full AVCO Calculator →

VYMETF

Seeks to track the performance of the FTSE High Dividend Yield Index, which measures the investment return of common stocks of companies characterized by high dividend yields. Provides a convenient way to track the performance of stocks that are forecasted to have above-average dividend yields. Follows a passively managed, full-replication approach.

Full VYM Calculator →
📬

Get this AVCO vs VYM comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AVCO vs SCHDAVCO vs JEPIAVCO vs OAVCO vs KOAVCO vs MAINAVCO vs VIGAVCO vs DGROAVCO vs HDV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.